Core Insights - CAMP4 Therapeutics presented positive translational data from its SYNGAP1-related disorders program, demonstrating efficacy in a humanized mouse model and increased protein levels in non-human primates at the ASGCT Annual Meeting [1][7] - The company reported a net loss of $12.6 million for Q2 2025, consistent with the loss from the same quarter in 2024 [8][13] - CAMP4 is advancing its CMP-SYNGAP-01 program with plans to initiate GLP toxicology studies in Q3 2025 and a potential global Phase 1/2 clinical trial in SYNGAP patients in H2 2026 [2][6] Corporate Highlights - The company has a strong pipeline focused on regulatory RNA-targeting therapeutics aimed at treating genetic diseases [1][9] - CMP-CPS-001 is being developed as a first-in-class, disease-modifying therapy for common urea cycle disorders (UCDs), with safety and biomarker data expected in Q4 2025 [2][6] Financial Results - As of June 30, 2025, CAMP4 had cash, cash equivalents, and marketable securities totaling $39.1 million, down from $49.3 million as of March 31, 2025 [4][13] - Research and development expenses for Q2 2025 were $10.3 million, an increase from $9.4 million in Q2 2024, primarily due to higher clinical and preclinical study costs [4][13] - General and administrative expenses rose to $4.2 million in Q2 2025 from $3.3 million in Q2 2024, driven by increased personnel-related and overhead costs [5][13]